@larpu_acc: on august 19 2026 moderna and merck announced the first successful late-stage results for a personalized mrna cancer vaccine. the vaccine is called intismeran (also known as intismeran autogene or previously mrna-4157/v940). it was tested in combination with merck’s immunotherapy drug keytruda in a phase 3 trial involving 1137 patients with high-risk stage iib to iv melanoma whose tumors had already been surgically removed. the trial met both its main goal of improving recurrence-free survival and a key secondary goal of improving distant metastasis-free survival. in plain terms the vaccine plus keytruda made it less likely for the melanoma to come back or spread to other parts of the body compared with keytruda alone. this is the first time a personalized neoantigen mrna cancer vaccine has succeeded in a large randomized phase 3 study. how it works: doctors sequence the patient’s tumor, identify unique mutations called neoantigens (up to 34 of them), and then use mrna technology to create a custom vaccine that teaches the immune system to recognize and attack those specific cancer markers. the whole manufacturing process takes roughly six weeks. earlier smaller trials had already shown roughly a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in the risk of distant spread or death over five years. the companies have not released the full detailed numbers yet but plan to present them at an upcoming medical conference. they are already talking with regulators about possible approval. some reports suggest the treatment could reach patients as early as next year if everything moves quickly. several sources also note that ai tools helped with selecting the best neoantigen targets for each patient. #larpochka #techtok #llm #machinelearning #claude

☣︎ larpochka ☣︎

Open In TikTok:

Region: DE

Thursday 20 August 2026 12:05:10 GMT